Sort   by:  
 Page size 
UnknownSingle-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Not available
S-EPMC4879693 | biostudies-literature
UnknownResults of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Not available
S-EPMC3646316 | biostudies-literature
UnknownNivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Not available
S-EPMC6075855 | biostudies-literature
UnknownMajor Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Not available
S-EPMC5877802 | biostudies-literature
UnknownSelf-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.
Not available
S-EPMC9403849 | biostudies-literature
Sort   by:  
 Page size